Alignment Healthcare Q2 2026: Net Income Swings to $36.6M, Membership Surges 31.5%, CEO Adopts 10b5-1 Plan
ALHC sits 33% above its 52-week low of $12.01.
Summary
Alignment Healthcare reported Q2 2026 net income of $36.6 million on revenue of $1.34 billion, with membership up 31.5%. CEO John Kao adopted a 10b5-1 trading plan, and the company disclosed new executive hires and a whistleblower lawsuit.
Key Events · Earnings and Guidance · ALHC
-
Q2 2026 Earnings Beat
Net income of $36.6 million ($0.17 diluted EPS) vs. $15.7 million a year ago. Revenue rose 31.6% to $1.34 billion, driven by 31.5% membership growth to 294,100. Medical benefits ratio improved to 86.3% from 86.7%.
-
CEO Adopts 10b5-1 Trading Plan
Chairman and CEO John Kao adopted a Rule 10b5-1 trading plan on May 27, 2026, for the sale of up to 800,000 shares between September 10, 2026 and February 26, 2027.
-
Senior Leadership Hires
Three new executive employment agreements disclosed: Shane Hochradel as COO ($650K base, 85% target bonus), Mark Kent as President - MSO ($650K base, 85% target bonus), and Joseph S. Konowiecki as EVP - Corporate Affairs ($700K base, 85% target bonus). Each received initial equity grants.
-
Whistleblower Lawsuit Filed
A former executive filed a lawsuit on July 7, 2026, alleging whistleblower retaliation and accounting irregularities. The company believes the claims are without merit and intends to defend vigorously. No accrual recorded.
Analysis · ALHC · Finance
Alignment Healthcare delivered a strong Q2 2026, swinging to a $36.6 million net profit from a $15.7 million profit a year ago on revenue that jumped 31.6% to $1.34 billion. Health plan membership grew 31.5% to 294,100, and the medical benefits ratio improved slightly. The company also disclosed that CEO John Kao adopted a 10b5-1 trading plan for up to 800,000 shares, and it entered into employment agreements with three new senior executives. A whistleblower lawsuit filed by a former executive alleging accounting irregularities adds a governance overhang, though the company says the claims are without merit.
At the time of this filing, ALHC was trading at $16.00 on NASDAQ in the Finance sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $12.01 to $25.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.